Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice

Aim. To study the frequency of prescribing anticoagulant therapy in outpatients with AF in accordance with clinical guidelines.Material and methods. Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF) observational study was conducted at the Saint Joasaph Belgorod Regional Clinical H...

Full description

Bibliographic Details
Main Authors: A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2020-03-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/2121
id doaj-a7c1e89339c34e59a417fb3e4096ce85
record_format Article
spelling doaj-a7c1e89339c34e59a417fb3e4096ce852021-09-03T13:15:30ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532020-03-01161192310.20996/1819-6446-2020-02-131697Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical PracticeA. A. Zarudsky0A. A. Gavrilova1Т. S. Filinichenko2Belgorod State National Research University, Medical InstituteBelgorod State National Research University, Medical InstituteBelgorod State National Research University, Medical InstituteAim. To study the frequency of prescribing anticoagulant therapy in outpatients with AF in accordance with clinical guidelines.Material and methods. Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF) observational study was conducted at the Saint Joasaph Belgorod Regional Clinical Hospital from January 1, 2016 to December 31, 2017. Patients with AF represented 15.5% of all patients admitted to cardiology department N1. 429 patients were included into the study: 203 women, 226 men; aged of 62.55±11.12 years. Exclusion criteria were mitral stenosis, mechanic prosthetic valve, first episode of AF. CHA2DS2-VASc score was used in all patients for calculation the risk of ischemic stroke and systemic thromboembolism. For patients that were treated by warfarin international normalization ratio (INR) was assessed at admission and discharge from the hospital.Results. From 429 patients 35 had 1 point according to the CHA2DS2-VASc scale, 393 (91.6%) patients had ≥2 points. Only 1 patient had 0 point. Therefore, most patients had absolute indications to anticoagulant therapy. At admission 60 (14%) patients received new oral anticoagulants (NOACs), 213 (49.6%) – warfarin, 156 (36.4%) – did not take any oral anticoagulant. Among patients receiving warfarin only 36 (8.4%) had target INR at admission. Therefore, effective anticoagulant therapy was observed only in 22.4% of patients in real clinical practice. Analyzing anticoagulant therapy in 2016 and 2017 we found a significant increase in NOAC prescription from 10.4% in 2016 to 18.9% in 2017 (p=0.0193).Conclusion. Our data reflects important gaps of anticoagulant therapy in real clinical practice. We compare our results with other Russian registries that included AF-patients. Data at admission and discharge suggests that there are great possibilities for optimization of anticoagulant therapy mainly with NOACs.https://www.rpcardio.com/jour/article/view/2121atrial fibrillationoral anticoagulantswarfarindabigatranapixabanrivaroxaban
collection DOAJ
language English
format Article
sources DOAJ
author A. A. Zarudsky
A. A. Gavrilova
Т. S. Filinichenko
spellingShingle A. A. Zarudsky
A. A. Gavrilova
Т. S. Filinichenko
Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
Racionalʹnaâ Farmakoterapiâ v Kardiologii
atrial fibrillation
oral anticoagulants
warfarin
dabigatran
apixaban
rivaroxaban
author_facet A. A. Zarudsky
A. A. Gavrilova
Т. S. Filinichenko
author_sort A. A. Zarudsky
title Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
title_short Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
title_full Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
title_fullStr Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
title_full_unstemmed Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
title_sort control of anticoagulation therapy in atrial fibrillation (coat-af study) in real clinical practice
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2020-03-01
description Aim. To study the frequency of prescribing anticoagulant therapy in outpatients with AF in accordance with clinical guidelines.Material and methods. Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF) observational study was conducted at the Saint Joasaph Belgorod Regional Clinical Hospital from January 1, 2016 to December 31, 2017. Patients with AF represented 15.5% of all patients admitted to cardiology department N1. 429 patients were included into the study: 203 women, 226 men; aged of 62.55±11.12 years. Exclusion criteria were mitral stenosis, mechanic prosthetic valve, first episode of AF. CHA2DS2-VASc score was used in all patients for calculation the risk of ischemic stroke and systemic thromboembolism. For patients that were treated by warfarin international normalization ratio (INR) was assessed at admission and discharge from the hospital.Results. From 429 patients 35 had 1 point according to the CHA2DS2-VASc scale, 393 (91.6%) patients had ≥2 points. Only 1 patient had 0 point. Therefore, most patients had absolute indications to anticoagulant therapy. At admission 60 (14%) patients received new oral anticoagulants (NOACs), 213 (49.6%) – warfarin, 156 (36.4%) – did not take any oral anticoagulant. Among patients receiving warfarin only 36 (8.4%) had target INR at admission. Therefore, effective anticoagulant therapy was observed only in 22.4% of patients in real clinical practice. Analyzing anticoagulant therapy in 2016 and 2017 we found a significant increase in NOAC prescription from 10.4% in 2016 to 18.9% in 2017 (p=0.0193).Conclusion. Our data reflects important gaps of anticoagulant therapy in real clinical practice. We compare our results with other Russian registries that included AF-patients. Data at admission and discharge suggests that there are great possibilities for optimization of anticoagulant therapy mainly with NOACs.
topic atrial fibrillation
oral anticoagulants
warfarin
dabigatran
apixaban
rivaroxaban
url https://www.rpcardio.com/jour/article/view/2121
work_keys_str_mv AT aazarudsky controlofanticoagulationtherapyinatrialfibrillationcoatafstudyinrealclinicalpractice
AT aagavrilova controlofanticoagulationtherapyinatrialfibrillationcoatafstudyinrealclinicalpractice
AT tsfilinichenko controlofanticoagulationtherapyinatrialfibrillationcoatafstudyinrealclinicalpractice
_version_ 1717816408934449152